Read more<\/a><\/div>\n<\/p>\n","protected":false},"author":761,"featured_media":28195,"comment_status":"closed","ping_status":"open","sticky":true,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14921,3,7640],"tags":[8765,15214,15215],"yoast_head":"\n
India Approves \u2018FabiFlu\u2019 to Treat Mild-Moderate COVID-19 Cases<\/title>\n<meta name=\"description\" content=\"Glenmark launched a new antiviral drug 'Favipiravir', with the brand name 'FabiFlu', for the treatment of mild to moderate Covid-19 patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nepalisansar.com\/coronavirus\/india-approves-fabiflu-to-treat-mild-moderate-covid-19-cases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"India Approves \u2018FabiFlu\u2019 to Treat Mild-Moderate COVID-19 Cases\" \/>\n<meta property=\"og:description\" content=\"Glenmark launched a new antiviral drug 'Favipiravir', with the brand name 'FabiFlu', for the treatment of mild to moderate Covid-19 patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nepalisansar.com\/coronavirus\/india-approves-fabiflu-to-treat-mild-moderate-covid-19-cases\/\" \/>\n<meta property=\"og:site_name\" content=\"Nepali Sansar\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/NepaliSansarNews\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-22T09:29:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-06-22T09:45:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.nepalisansar.com\/wp-content\/uploads\/2020\/06\/live-fabiflu-to-treat-covid-19-in-India-update.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nepali Sansar Bureau\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@nepalisansar4u\" \/>\n<meta name=\"twitter:site\" content=\"@nepalisansar4u\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nepali Sansar Bureau\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.nepalisansar.com\/coronavirus\/india-approves-fabiflu-to-treat-mild-moderate-covid-19-cases\/\",\"url\":\"https:\/\/www.nepalisansar.com\/coronavirus\/india-approves-fabiflu-to-treat-mild-moderate-covid-19-cases\/\",\"name\":\"India Approves \u2018FabiFlu\u2019 to Treat Mild-Moderate COVID-19 Cases\",\"isPartOf\":{\"@id\":\"https:\/\/www.nepalisansar.com\/#website\"},\"datePublished\":\"2020-06-22T09:29:33+00:00\",\"dateModified\":\"2020-06-22T09:45:21+00:00\",\"author\":{\"@id\":\"https:\/\/www.nepalisansar.com\/#\/schema\/person\/0b1cc737a429a92681b510a50f2d99e4\"},\"description\":\"Glenmark launched a new antiviral drug 'Favipiravir', with the brand name 'FabiFlu', for the treatment of mild to moderate Covid-19 patients.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.nepalisansar.com\/coronavirus\/india-approves-fabiflu-to-treat-mild-moderate-covid-19-cases\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.nepalisansar.com\/coronavirus\/india-approves-fabiflu-to-treat-mild-moderate-covid-19-cases\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.nepalisansar.com\/coronavirus\/india-approves-fabiflu-to-treat-mild-moderate-covid-19-cases\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.nepalisansar.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"India Approves \u2018FabiFlu\u2019 to Treat Mild-Moderate COVID-19 Cases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.nepalisansar.com\/#website\",\"url\":\"https:\/\/www.nepalisansar.com\/\",\"name\":\"Nepali Sansar\",\"description\":\" A Site for Global Nepali Community\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.nepalisansar.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.nepalisansar.com\/#\/schema\/person\/0b1cc737a429a92681b510a50f2d99e4\",\"name\":\"Nepali Sansar Bureau\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.nepalisansar.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/b1144069b2c7a064938644bed31e4763?s=96&d=wavatar&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/b1144069b2c7a064938644bed31e4763?s=96&d=wavatar&r=g\",\"caption\":\"Nepali Sansar Bureau\"},\"description\":\"This is the News Bureau of Nepali Sansar, a US-based media house that covers all the major happenings and updates related to Nepal.\",\"sameAs\":[\"https:\/\/www.nepalisansar.com\/\"],\"url\":\"https:\/\/www.nepalisansar.com\/author\/nepalisansarbureau\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"India Approves \u2018FabiFlu\u2019 to Treat Mild-Moderate COVID-19 Cases","description":"Glenmark launched a new antiviral drug 'Favipiravir', with the brand name 'FabiFlu', for the treatment of mild to moderate Covid-19 patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nepalisansar.com\/coronavirus\/india-approves-fabiflu-to-treat-mild-moderate-covid-19-cases\/","og_locale":"en_US","og_type":"article","og_title":"India Approves \u2018FabiFlu\u2019 to Treat Mild-Moderate COVID-19 Cases","og_description":"Glenmark launched a new antiviral drug 'Favipiravir', with the brand name 'FabiFlu', for the treatment of mild to moderate Covid-19 patients.","og_url":"https:\/\/www.nepalisansar.com\/coronavirus\/india-approves-fabiflu-to-treat-mild-moderate-covid-19-cases\/","og_site_name":"Nepali Sansar","article_publisher":"https:\/\/www.facebook.com\/NepaliSansarNews\/","article_published_time":"2020-06-22T09:29:33+00:00","article_modified_time":"2020-06-22T09:45:21+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/www.nepalisansar.com\/wp-content\/uploads\/2020\/06\/live-fabiflu-to-treat-covid-19-in-India-update.jpg","type":"image\/jpeg"}],"author":"Nepali Sansar Bureau","twitter_card":"summary_large_image","twitter_creator":"@nepalisansar4u","twitter_site":"@nepalisansar4u","twitter_misc":{"Written by":"Nepali Sansar Bureau","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.nepalisansar.com\/coronavirus\/india-approves-fabiflu-to-treat-mild-moderate-covid-19-cases\/","url":"https:\/\/www.nepalisansar.com\/coronavirus\/india-approves-fabiflu-to-treat-mild-moderate-covid-19-cases\/","name":"India Approves \u2018FabiFlu\u2019 to Treat Mild-Moderate COVID-19 Cases","isPartOf":{"@id":"https:\/\/www.nepalisansar.com\/#website"},"datePublished":"2020-06-22T09:29:33+00:00","dateModified":"2020-06-22T09:45:21+00:00","author":{"@id":"https:\/\/www.nepalisansar.com\/#\/schema\/person\/0b1cc737a429a92681b510a50f2d99e4"},"description":"Glenmark launched a new antiviral drug 'Favipiravir', with the brand name 'FabiFlu', for the treatment of mild to moderate Covid-19 patients.","breadcrumb":{"@id":"https:\/\/www.nepalisansar.com\/coronavirus\/india-approves-fabiflu-to-treat-mild-moderate-covid-19-cases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nepalisansar.com\/coronavirus\/india-approves-fabiflu-to-treat-mild-moderate-covid-19-cases\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.nepalisansar.com\/coronavirus\/india-approves-fabiflu-to-treat-mild-moderate-covid-19-cases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.nepalisansar.com\/"},{"@type":"ListItem","position":2,"name":"India Approves \u2018FabiFlu\u2019 to Treat Mild-Moderate COVID-19 Cases"}]},{"@type":"WebSite","@id":"https:\/\/www.nepalisansar.com\/#website","url":"https:\/\/www.nepalisansar.com\/","name":"Nepali Sansar","description":" A Site for Global Nepali Community","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nepalisansar.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.nepalisansar.com\/#\/schema\/person\/0b1cc737a429a92681b510a50f2d99e4","name":"Nepali Sansar Bureau","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.nepalisansar.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/b1144069b2c7a064938644bed31e4763?s=96&d=wavatar&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b1144069b2c7a064938644bed31e4763?s=96&d=wavatar&r=g","caption":"Nepali Sansar Bureau"},"description":"This is the News Bureau of Nepali Sansar, a US-based media house that covers all the major happenings and updates related to Nepal.","sameAs":["https:\/\/www.nepalisansar.com\/"],"url":"https:\/\/www.nepalisansar.com\/author\/nepalisansarbureau\/"}]}},"_links":{"self":[{"href":"https:\/\/www.nepalisansar.com\/wp-json\/wp\/v2\/posts\/28193"}],"collection":[{"href":"https:\/\/www.nepalisansar.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nepalisansar.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nepalisansar.com\/wp-json\/wp\/v2\/users\/761"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nepalisansar.com\/wp-json\/wp\/v2\/comments?post=28193"}],"version-history":[{"count":0,"href":"https:\/\/www.nepalisansar.com\/wp-json\/wp\/v2\/posts\/28193\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.nepalisansar.com\/wp-json\/wp\/v2\/media\/28195"}],"wp:attachment":[{"href":"https:\/\/www.nepalisansar.com\/wp-json\/wp\/v2\/media?parent=28193"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nepalisansar.com\/wp-json\/wp\/v2\/categories?post=28193"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nepalisansar.com\/wp-json\/wp\/v2\/tags?post=28193"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"Notable](\"https:\/\/www.nepalisansar.com\/wp-content\/uploads\/2020\/06\/fabiflu-to-treat-covid-19-in-India.jpg\" "\\"Notable")
<\/p>\n![\"FabiFlu](\"https:\/\/www.nepalisansar.com\/wp-content\/uploads\/2020\/06\/notable-features-of-fabiflu.jpg\" "\\"FabiFlu")
<\/p>\n